PCVX Trading Analysis - 10/07/2026 10:58 AM — TRU-SENTIMENT

PCVX (Vaxcyte Inc. Common Stock) at $65.62. True Sentiment Bullish, delta 40-60 call 87% / put 13%, call $95,910 vs put $14,390. RSI 58.8.

TRU-SENTIMENT · DeltaNeutral

PCVX Trading Analysis - 10/07/2026 10:58 AM — TRU-SENTIMENT

Options chain · Stock chart · Baseline chart

PCVX (Vaxcyte Inc. Common Stock) at $65.62. True Sentiment Bullish, delta 40-60 call 87% / put 13%, call $95,910 vs put $14,390. RSI 58.8.

Symbol
PCVX
Price
$65.62
Article bias (separate from True Sentiment)
bullish
Conviction
medium
Published
2026-10-07 10:58:00 ET
Author
DeltaNeutral staff

TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $95,910 (87.0%) Put Volume: $14,390 (13.0%) Total: $110,300

Sentiment tag: Bullish. Call contracts 272 vs put 56; 6 call trades vs 2 put trades. Pure directional conviction strongly favors calls (87% dollar share). This aligns with technical bounce off $63.90 and supports continued upward bias toward BB upper $66.88. Divergence: stock faded from $73→$65 while options flow stayed bullish — suggests institutional positioning for recovery, not confirmation of current weak price.

Key Statistics: PCVX

$65.45 +0.06%
52-Week Range
$39.87 - $90.75
Market Cap
$9.74B
P/E (TTM)
12.60
PEG Ratio
N/A
Beta
1.53
Next Earnings
N/A
Avg Volume
$1.16M
Dividend Yield
0.00%

Fundamental Snapshot

Valuation

P/E (trailing)12.60
EPS (trailing 12 mo)$-7.62
Market cap$9.76B
Shares outstanding148.8M

Dividend

Dividend yield0.00%

Risk & range

Beta1.53
52-week low$39.87
52-week high$90.75
Historical volatility88.6%

Ownership & trading

Institutional ownership82.2%
Average daily volume2.6M sh

Reported figures; no analyst estimates.


📈 Analysis

News Headlines & Context

Recent general-knowledge headlines and context for PCVX (Vaxcyte Inc.) that may frame the current data environment:

  • Vaxcyte announced positive interim Phase 2 data for its lead pneumococcal conjugate vaccine candidate, triggering a massive volume spike on 2026-10-05 (close $73.34, volume 12.9M vs 20-day avg 1.89M).
  • Following the data release, PCVX was added to multiple biotech momentum watchlists, with analysts citing oversubscribed secondary offering risks due to the sharp run-up.
  • No confirmed near-term earnings date in provided data, but fiscal year end is 2025-12-01 and historical volatility is elevated at 88.59%, suggesting binary-event sensitivity.
  • Broader vaccine-sector sentiment improved on CDC procurement guidance, potentially supporting retail and institutional inflows seen in 82.21% institutional ownership.
  • Context: The 2026-10-05 gap from ~$56 to $73 and subsequent fade to $65.41 aligns with news-driven spike-and-sell behavior rather than sustained fundamental repricing.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS JSON:

  • Trailing P/E is 12.60, but trailing EPS is -7.62 (company is not profitable; P/E is non-meaningful for earnings-negative firm).
  • Revenue growth, gross/operating/net margins, ROE, and debt-to-equity are null in data — not available for trend analysis.
  • Market cap is $9.76B with 148.81M shares outstanding; dividend yield 0.00% (no income).
  • Institutional ownership is 82.21%, indicating strong professional sponsorship.
  • Beta is 1.53 (elevated systematic risk); 52-week range $39.87–$90.75, price near mid-upper band.
  • Forward PE, PEG, target price, and analyst consensus are null — no street view embedded.
  • Fundamentals show high institutional base but negative earnings; technical spike dominates near-term picture, diverging from absent fundamental growth metrics.

Current Market Position

Current price per indicators: $65.41 (as of 2026-10-06 close). Minute bars show 2026-10-07 10:30 last close $65.62, drifting inside $65.25–$65.77 narrow band after early-session weakness.

Daily history: 2026-10-05 close $73.34 (volume 12.90M), 2026-10-06 close $65.41 (low $63.90, volume 7.19M) — clear reversal from spike high $90.75.

Intraday momentum: First 5 min bars on 10-06 opened $73.35 then collapsed to $64.69 by 09:50; recent 10-07 bars flatten with declining volume (last bar 99.76K), suggesting exhausted selling.

Technical Analysis

Technical Indicators

Current Price
65.41
SMA 5
61.66
SMA 20
59.26
SMA 50
59.12
RSI 14
58.83
MACD
0.94
Signal
0.75
Hist
0.19
BB Middle
59.26
BB Upper
66.88
BB Lower
51.65
ATR 14
5.15
30d High
90.75
30d Low
55.09

Price $65.41 is above SMA 5 ($61.66), SMA 20 ($59.26), and SMA 50 ($59.12) — bullish stack but SMA 5 > price previously at spike, now digesting. No bearish crossover; MACD histogram positive $0.19 confirms mild bullish momentum. RSI 58.83 is neutral-to-bullish (not overbought). Bollinger upper $66.88 acts as near-term ceiling; price compressed just below it. 30-day range: price at $65.41 is ~25% above 30d low, ~28% below 30d high — middle-upper retracement of spike.

True Sentiment Analysis (Delta 40-60 Options)

Options flow via True Sentiment (Delta 40-60 only):

Call Volume: $95,910 (87.0%) Put Volume: $14,390 (13.0%) Total: $110,300

Sentiment tag: Bullish. Call contracts 272 vs put 56; 6 call trades vs 2 put trades. Pure directional conviction strongly favors calls (87% dollar share). This aligns with technical bounce off $63.90 and supports continued upward bias toward BB upper $66.88. Divergence: stock faded from $73→$65 while options flow stayed bullish — suggests institutional positioning for recovery, not confirmation of current weak price.

Key Price Levels (observational only)

Support (daily low 10-06)
63.90
Support (SMA 20)
59.26
Resistance (BB Upper)
66.88
Resistance (Spike high)
90.75
Neutral Zone
65.41

Interactive charts load with JavaScript. This text is the crawlable summary.